Pharma Times -- GlaxoSmithKline’s fallen diabetes drug Avandia has taken another hit after research in the British Medical Journal added further weight to evidence that the drug could put patients at an increased risk from heart disease.
Pharma Times -- GlaxoSmithKline’s fallen diabetes drug Avandia has taken another hit after research in the British Medical Journal added further weight to evidence that the drug could put patients at an increased risk from heart disease.
